Intervention

fludeoxyglucose F 18

ClinicalTrials.gov intervention label

Clinical trials25
Recruiting0
Common conditions25
Lead sponsors shown15

Clinical trials

25 shown
Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast CancerNCT02226276 · 2015-01-07
ACTIVE_NOT_RECRUITING
Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung CancerNCT02059889 · 2014-07-01
WITHDRAWN
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone TherapyNCT01720602 · 2012-11-01
COMPLETED
FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast CancerNCT01931709 · 2011-11-01
TERMINATED
Methylprednisolone Before Fludeoxyglucose-Labeled Positron Emission Tomography in Patients With Lung CancerNCT01789892 · 2011-06-01
WITHDRAWN
Fludeoxyglucose F 18 PET/CT Scans in Predicting Therapy Response in Patients With Stage IIIA Non-Small Cell Lung Cancer Undergoing ChemoradiationNCT01314677 · 2011-04-01
WITHDRAWN
Fluorine F18-EF5 and Fludeoxyglucose F18 Positron Emission Tomography in Assessing Hypoxia and Glycolysis in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung CancerNCT01017133 · 2009-05-01
COMPLETED
Sunitinib Malate in Treating Patients With Small Cell Lung CancerNCT00953459 · 2009-02-01
TERMINATED
Stereotactic Radiosurgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung CancerNCT00852644 · 2009-01-01
TERMINATED
F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast CancerNCT00602043 · 2008-09-01
COMPLETED
Fludeoxyglucose F 18 in Detecting Lymph Node Metastasis in Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed by SurgeryNCT00732563 · 2008-07-16
COMPLETED
FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung CancerNCT00564733 · 2007-10-01
COMPLETED
Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast CancerNCT00755313 · 2007-05-01
COMPLETED
Positron Emission Tomography and Computed Tomography in Planning Treatment for Patients Undergoing 3-Dimensional Conformal Radiation Therapy for Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery. ICORG 06-35NCT00958321 · 2007-03-01
TERMINATED
Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck CancerNCT01254591 · 2006-11-01
UNKNOWN
PET Scans in Assessing Response To Treatment in Patients Receiving Hormone Therapy or Trastuzumab for Breast CancerNCT00362973 · 2006-05-01
COMPLETED
Positron Emission Tomography in Predicting Response in Patients Who Are Undergoing Treatment With Pemetrexed Disodium and Cisplatin With or Without Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung CancerNCT00227539 · 2005-07-01
COMPLETED
Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung CancerNCT00083083 · 2005-03-01
UNKNOWN
Glucose Metabolism in Patients With Non-Small Cell Lung Cancer Treated With Targeted Therapy and ChemotherapyNCT00450567 · 2004-12-01
COMPLETED
11C Topotecan PET ImagingNCT00253461 · 2004-12-01
TERMINATED
Positron Emission Tomography Before Surgery in Evaluating Women With Primary or Recurrent Breast CancerNCT00039286 · 2001-10-01
COMPLETED
Positron Emission Tomography for Detecting Non-small Cell Lung CancerNCT00004138 · 1999-09-01
COMPLETED
PET Scans in Patients With Locally Advanced Breast CancerNCT00109785 · 1997-03-01
COMPLETED
PET Scan in Treating Patients With Metastatic Prostate CancerNCT00002981 · 1997-01-01
COMPLETED
PET Scan in Patients With Lung and Esophageal Cancers That May Be Removed by SurgeryNCT00002930 · 1996-12-01
COMPLETED

Common conditions

Lung Cancer12Breast Cancer5Recurrent Breast Cancer3Stage IV Breast Cancer3Esophageal Cancer2Male Breast Cancer2Metastatic Cancer2Stage IIIA Non-small Cell Lung Cancer2Stage IIIB Non-small Cell Lung Cancer2Bone Metastases1Chemotherapeutic Agent Toxicity1Cognitive/Functional Effects1Colorectal Cancer1Estrogen Receptor-positive Breast Cancer1Fatigue1Head and Neck Cancer1HER2-positive Breast Cancer1Liver Metastases1Long-term Effects Secondary to Cancer Therapy in Adults1Lung Metastases1Malignant Pleural Effusion1Neurotoxicity1Non-small Cell Lung Cancer1Ovarian Cancer1Progesterone Receptor-negative Breast Cancer1

Leading sponsors

University of Washington5Memorial Sloan Kettering Cancer Center4City of Hope Medical Center2Abramson Cancer Center at Penn Medicine1Alliance for Clinical Trials in Oncology1American College of Radiology Imaging Network1Boston Medical Center1Cancer Trials Ireland1Case Comprehensive Cancer Center1European Organisation for Research and Treatment of Cancer - EORTC1Jonsson Comprehensive Cancer Center1National Cancer Institute (NCI)1Ohio State University Comprehensive Cancer Center1Roswell Park Cancer Institute1University College London (UCL) Cancer Institute1

Trial status mix

COMPLETED14
TERMINATED5
WITHDRAWN3
UNKNOWN2
ACTIVE_NOT_RECRUITING1

Phase mix

NA11
PHASE27
PHASE13
EARLY_PHASE11
PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.